Crescent Biopharma Announces Grants of Inducement Awards

Core Points - Crescent Biopharma, Inc. has granted options to purchase a total of 451,448 shares to eight non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan [1] - The options have a 10-year term with an exercise price of $13.02, which is the closing price on November 14, 2025 [2] - The vesting schedule for the options includes one-fourth vesting on the first anniversary of the employee's start date, followed by monthly vesting of one-forty-eighth thereafter [2] Company Overview - Crescent Biopharma aims to become a leading oncology company focused on developing innovative therapies for cancer patients [3] - The company's pipeline features a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) [3] - Crescent Biopharma intends to leverage multiple modalities and established targets to advance transformative therapies for various solid tumors [3]